Michael Palladinetti, global head of business development and licensing at Sanofi, told delegates attending Bio Europe Spring in Barcelona, Spain last week that history has shown us time and time again that no one has the monopoly on the next wave of innovation. Citing the recent GLP-1 wave, Palladinetti said the industry has a bit of fear of missing out (FOMO) and paid kudos to Lily and Novo for staying in the space. He added how innovation is also very difficult and that industry players need to have a broad view. Both firms are pioneers in the diabetes space, having launched their own versions of insulin over 100 years ago
The meaningful question for you personally is whether you're a clinical candidate for GLP-1 treatment - that's a conversation with a licensed provider, which is exactly what the enrollment process provides
Centers for Disease Control and Prevention, over one third of children consume dietary supplements
doi: 10.1155/2021/6640600, 127
For those who want ultra-specific treatments, Equinox may not be the fit
Our UK-dispatched peptide range is trusted by laboratories and qualified researchers seeking high-purity research compounds with consistent batch quality and verified specifications
